首页 | 本学科首页   官方微博 | 高级检索  
     

125Ⅰ粒子源近距离治疗前列腺癌模型的剂量学研究
引用本文:马蕊,苑淑渝,孔令海,张良安. 125Ⅰ粒子源近距离治疗前列腺癌模型的剂量学研究[J]. 中华放射医学与防护杂志, 2011, 31(4): 485-488
作者姓名:马蕊  苑淑渝  孔令海  张良安
作者单位:300192 天津,中国医学科学院 北京协和医学院放射医学研究所 天津市分子核医学重点实验室;300192 天津,中国医学科学院 北京协和医学院放射医学研究所 天津市分子核医学重点实验室;300192 天津,中国医学科学院 北京协和医学院放射医学研究所 天津市分子核医学重点实验室;300192 天津,中国医学科学院 北京协和医学院放射医学研究所 天津市分子核医学重点实验室
摘    要:目的 研究放射性125Ⅰ粒子源在治疗前列腺癌中的剂量分布,探寻治疗计划系统(TPS)优化效果的有效方法.方法 选定1个治疗计划系统,应用热释光剂量计,基于前列腺癌等效模体,模拟测量前列腺癌中的剂量分布.模拟植入共89颗125Ⅰ粒子,每个粒子的活度为1.37×107Bq(±5%).结果 各层的最大剂量为151~241 G...

关 键 词:近距离治疗  热释光剂量计  前列腺癌  125Ⅰ粒子源
收稿时间:2010-04-12

Dose distribution of 125I seed sources in brachytherapy prostate cancer model
MA Rui,YUAN Shu-yu,KONG Ling-hai and ZHANG Liang-an. Dose distribution of 125I seed sources in brachytherapy prostate cancer model[J]. Chinese Journal of Radiological Medicine and Protection, 2011, 31(4): 485-488
Authors:MA Rui  YUAN Shu-yu  KONG Ling-hai  ZHANG Liang-an
Affiliation:Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192,China;Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192,China;Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192,China;Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin 300192,China
Abstract:Objective To study the dose distribution of the radioactive 125I seeds sources in the treatment of prostate cancer and also to explore the more effective method for improving treatment planning system (TPS). Methods Choose the designated TPS and use TLDs dosimeter based on a prostate cancer model. Finally stimulated measurement was focused on dose distribution in prostate cancer. The number of 125I seed sources implanted was 89, each with 1.37×107 (±5%) Bq. Results Maximum dose of every layer ranged from 151 to 241 Gy, by 4.1% to 66.0% higher than the prescribed dose (145 Gy). The Minimum dose of every layer ranged from 101 to 128 Gy, by 12% to 30% higher than the prescribed dose. The maximum dose of normal tissue at 10 mm from the edge of model ranged from 46 to 91 Gy. The deviation was 44%-63% compared with the prescribed dose. Conclusions The designated TPS shows that it could be used as a practical guide for treatment of prostate cancer with the radioactive 125I seed sources. The research methods offered by the study can provide evaluation of the TPS.
Keywords:Brachytherapy  TLDs  Prostate cancer  Iodine-125 seed source
点击此处可从《中华放射医学与防护杂志》浏览原始摘要信息
点击此处可从《中华放射医学与防护杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号